Wang Jie, Xie Lan-Gui, Wu Xian-Fu, Zhao Zong-Ge, Yang Hui-Ying, Sun Hui-Min
National Institutes for Food and Drug Control, Beijing, 100260, PR China.
Heliyon. 2024 Jul 27;10(15):e35101. doi: 10.1016/j.heliyon.2024.e35101. eCollection 2024 Aug 15.
Micro-nano-plastic (MNP) particles (p) in the environment can enter the human body and pose a potential threat to human health. However, it is unknown whether these substances are present in polypropylene (PP) plastic-bottled injections, which are used as high-frequency intravenous infusions to treat diseases. Therefore, the objective of this study was to identify and quantify insoluble MNP particles in 16 batches of injectable formulations within the validity period. Primarily, ethylene-propylene copolymer or P(E-P) micro-plastic (MP) particles (2-10 μm, 216 p/mL) were identified by micro-Raman spectroscopy, and nano-particles (50 nm, 2.1 × 10 p/mL) similar to PP containing only carbon were detected by scanning electron microscopy-energy-dispersive X-ray spectroscopy (photoelectron). Furthermore, P(E-P) MP particles (1 × 10 to 1 × 10 ng/L) from the injections were enriched on the GF-B filter, and PP or P(E-P) nano-plastic (NP) particles (1 × 10 to 4 × 10 ng/L) enriched on the alumina film were detected by pyrolysis-gas chromatography/mass spectrometry. Finally, the total insoluble particles in injections were 6 × 10 to 1 × 10 p/mL (0.02-100 μm). Our findings are the first to identify and quantify MNPs in PP-bottled injections. Considering that they can enter the blood circulation, so whether cause disease remains to be investigated.
环境中的微纳塑料(MNP)颗粒可进入人体并对人类健康构成潜在威胁。然而,这些物质是否存在于用作高频静脉注射治疗疾病的聚丙烯(PP)塑料瓶装注射液中尚不清楚。因此,本研究的目的是鉴定和定量16批次有效期内可注射制剂中的不溶性MNP颗粒。首先,通过显微拉曼光谱法鉴定出乙烯-丙烯共聚物或P(E-P)微塑料(MP)颗粒(2-10μm,216个颗粒/毫升),并通过扫描电子显微镜-能量色散X射线光谱法(光电子)检测到仅含碳的类似于PP的纳米颗粒(50nm,2.1×10个颗粒/毫升)。此外,注射液中的P(E-P)MP颗粒(1×10至1×10纳克/升)在GF-B滤膜上富集,通过热解气相色谱/质谱法检测在氧化铝膜上富集的PP或P(E-P)纳米塑料(NP)颗粒(1×10至4×10纳克/升)。最后,注射液中的总不溶性颗粒为6×10至1×10个颗粒/毫升(0.02-100μm)。我们的研究结果首次鉴定并定量了PP瓶装注射液中的MNP。考虑到它们可进入血液循环,因此是否会引发疾病仍有待研究。